Create an Account
  1. Home
  2. Specialty
  3. Retina

KOL Knockout™: Retina Edition – Treatment Outcomes to Vie For – Round 2

KOL Knockout Retina Edition Treatment Outcomes to Vie For Round 2
Media formats available:
Details
Presenters

  • Overview

    Round 2 of this exciting CME program was filmed in Chicago! Hosted by Program Chair Sunil K. Srivastava, MD, it features contestants Yasha S. Modi, MD; Priya Sharma Vakharia, MD (Round 1 winner); and Christina Y. Weng, MD, MBA.

    This content was captured during a live virtual symposium. Voting took place during the symposium.

    There will be learning, laughter, and only one KOL left standing!

     

    This activity is supported by independent educational grants from Bausch + Lomb and Genentech, a member of the Roche Group.

     

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Recognize the barriers to early diagnosis and intervention for patients with retinal disease
    • Evaluate key data from clinical studies to determine the medical and surgical treatment approaches that would be most effective in managing disease presentation in real-world settings
    • Describe the role of visualization in common vitreoretinal surgical procedure
    • Formulate troubleshooting guides to mitigate the effect of unexpected intraoperative vitreous behavior
    • Develop algorithms to identify and surgically treat patients who may benefit from cutting-edge durable therapies for the treatment of diabetic eye diseases and neovascular age-related macular degeneration

    • Accreditation

      Provided by Evolve Medical Education 

      Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
      Evolve designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

       

    • Participation Method

      In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

    • Faculty and Disclosures

      Sunil K. Srivastava, MD

      Sunil K. Srivastava, MD

      Surgical Retina Fellowship Director
      Cleveland Clinic Cole Eye Institute
      Cleveland, OH


      Yasha S. Modi, MD

      Yasha S. Modi, MD

      Associate Professor of Ophthalmology

      Department of Ophthalmology

      Director of Tele-Retina NYU Langone Health

      New York, NY


      Priya Sharma Vakharia, MD

      Priya Sharma Vakharia, MD

      Retina Vitreous Associates of Florida

      Palm Harbor and St. Petersburg, FL


      Christina Y. Weng, MD, MBA

      Christina Y. Weng, MD, MBA

      Professor of Ophthalmology

      Fellowship Program Director

      Vitreoretinal Diseases & Surgery

      Baylor College of Medicine

      Houston, TX


      DISCLOSURE POLICY
      It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

      The following faculty/staff members have the following financial relationships with ineligible companies.

      Sunil K. Srivastava, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Adverum Biotechnologies, Allergan, Bausch + Lomb, Carl Zeiss Meditec, EyePoint Pharmaceuticals, Eyevensys, jCyte, Novartis, and Regeneron Pharmaceuticals. Grant/Research Support: Bausch + Lomb, EyePoint Pharmaceuticals, Eyevensys, jCyte, Novartis, and Regeneron Pharmaceuticals.

      Yasha S. Modi, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alimera Sciences, Allergan/AbbVie, Carl Zeiss Meditec, DORC, Genentech, Iveric Bio, and Théa Pharma.

      Priya Sharma Vakharia, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alimera Sciences, Bausch + Lomb, Genentech, Gyroscope Therapeutics, Notal Vision, and Regeneron Pharmaceuticals. Grant/Research Support: Alkahest, Annexon, AsclepiX Therapeutics, Bayer, Chengdu Kanghong, Biotech (PANDA Trial stopped 04/2021), EyePoint Pharmaceuticals, Gemini Therapeutics, Genentech, Gyroscope Therapeutics, Ionis Pharmaceuticals, Iveric Bio, Kodiak Sciences, Mylan, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, Opthea, RecensMedical, Regeneron Pharmaceuticals, RegenxBio, and Unity. Speaker's Bureau: Bausch + Lomb, Genentech, and Heidelberg Engineering. Stock/Shareholder: Network Eye and Quad-C/Prism Vision Group.

      Christina Y. Weng, MD, MBA, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Alimera Sciences, Allergan/AbbVie, DORC, Genentech, Novartis, Regeneron Pharmaceuticals, and RegenxBio. Grant/Research Support: AGTC, Alimera Sciences, and DRCR Retina Network.

      The Evolve staff and planners have no financial relationships with ineligible companies.
      Nisha Mukherjee, MD, peer reviewer, has no financial relationships with ineligible companies.

    • Disclaimer

      OFF-LABEL STATEMENT
      This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

      DISCLAIMER
      The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Bausch + Lomb, or Genentech, a member of the Roche Group.

      This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

      This program is not affiliated with the official program of AAO 2022.

       

    • System Requirements

      • Supported Browsers (2 most recent versions):
        • Google Chrome for Windows, Mac OS, iOS, and Android
        • Apple Safari for Mac OS and iOS
        • Mozilla Firefox for Windows, Mac OS, iOS, and Android
        • Microsoft Edge for Windows
      • Recommended Internet Speed: 5Mbps+

    • Publication Dates

      Release Date:

      Expiration Date:

    Ready to Claim Your Credits?

    You have attempts to pass this post-test. Take your time and review carefully before submitting.

    Good luck!

    LIVE ON REACHMD RADIOBack to live radio
    ReachMD Radio

    Loading...

    00:00
    00:00
      Register

      We're glad to see you're enjoying Evolve Medical Education…
      but how about a more personalized experience?

      Register for free